We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Fujifilm is betting that Avigan, which inhibits the RNA polymerase enabling the flu virus to replicate, will work against the coronavirus, another RNA virus. Read More
In December, GSK and Sanofi suffered a setback during their phase 1/2 trial, when their vaccine was found to produce only a weak immune response in older patients. Read More
Roughly three-quarters of women enrolled in the trial saw a 50 percent or greater reductions from baseline in menstrual blood loss volume during the last 35 days of treatment. Read More
GlaxoSmithKline (GSK) and Sanofi have launched a phase 2 study evaluating their adjuvanted recombinant COVID-19 candidate, after delaying the trial by more than two months. Read More
Novavax has announced that it has completed enrolling 30,000 participants in its late-stage U.S./Mexico pivotal trial of its COVID-19 vaccine, bringing its recombinant protein-based vaccine hopeful one step closer to potential FDA authorization. Read More
The small-scale trial will include up to 90 healthy adult volunteers age 18 to 30 years who will be exposed to the virus in a controlled setting. Read More
An analysis by researchers at the University of Oxford has found that the AstraZeneca (AZ)/Oxford coronavirus vaccine appears more effective when its two doses are administered three months apart, results in line with those unveiled by AZ earlier this month. Read More
A study conducted in Israel, which has already vaccinated a large percentage of its population, has found that a single dose of Pfizer/BioNTech’s COVID-19 vaccine is highly effective at reducing infection, lending more support to the strategy of delaying second doses to increase initial vaccinations. Read More
Pfizer and BioNTech announced that they have dosed the first patients in a global study evaluating their COVID-19 vaccine in pregnant women 18 years and over. Read More
A statistical analysis of multiple clinical trials that assessed Fujifilm’s antiviral Avigan (favipiravir) as a COVID-19 treatment has found that the drug showed limited efficacy in reducing mortality unless given early to infected patients. Read More